Ustekinumab Drug Survival in Patients with Psoriasis: A retrospective Study of Real Clinical Practice

Autor: Cristina Galache Osuna, Borja Gómez-Vila, Javier Aubán Pariente, Beatriz Vázquez Losada, Celia Gómez de Castro, Sheila Requena López, Álvaro de Dios Velázquez, Laura Palacios García, Lucía Ordoñez Fernández, Santiago Gómez Diez, Francisco Vázquez López, Jorge Santos-Juanes
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: Medicina, Vol 56, Iss 11, p 584 (2020)
Druh dokumentu: article
ISSN: 1648-9144
1010-660X
DOI: 10.3390/medicina56110584
Popis: Background and objectives: The efficacy and safety of ustekinumab have been proved in clinical trials. In daily clinical practice, knowing the factors that determine survival differences of biological drugs allows psoriasis treatment to be optimized as a function of patient characteristics. The main objectives of this work are to understand ustekinumab drug survival in patients diagnosed with plaque psoriasis in the Hospital Universitario Central de Asturias (HUCA Dermatology Department, and to identify the predictors of drug discontinuation. Materials and Methods: A retrospective hospital-based study, including data from 148 patients who were receiving ustekinumab (Stelara®) between 1 February 2009 and 30 November 2019, were collected. Survival curves were approximated through the Kaplan–Meier estimator and compared using the log-rank test. Proportional hazard Cox regression models were used for multivariate analyses while both unadjusted and adjusted hazard ratios (HR) were used for summarizing the studied differences. Results: The average duration of the treatment before discontinuation was 47.57 months (SD 32.63 months; median 41 months). The retention rates were 82% (2 years), 66% (5 years), and 58% (8 years). Median survival was 80 months (95% confidence interval. CI 36.9 to 123.01 months). The survival study revealed statistically significant differences between patients with arthritis (log-rank test, p < 0.001) and those who had previously received biological treatment (log-rank test, p = 0.026). The five-year prevalence in patients still under treatment was 80% (those without arthritis) and 54% (arthritis patients). In the multivariate analysis, only the patients with arthritis had a lower rate of drug survival. No statistically significant differences were observed for any of the other comorbidities studied. The first and second most frequent causes of discontinuation were secondary failure and arthritis inefficacy, respectively. Conclusion: Ustekinumab is a biological drug conferring high survival in plaque psoriasis patients. Ustekinumab survival is lower in patients with arthritis.
Databáze: Directory of Open Access Journals
Externí odkaz: